Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells

Leukemia

Volumn 17, Issue 6, 2003, Pages 1068-1077

  Metelitsa, L S ^a   Weinberg, K I ^b   Emanuel, P D ^c   Seeger, R C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

CD1d; Immunotherapy; Myeloid leukemia; NKT cells; galactosylceramide

Indexed keywords

CD1D ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; FAS LIGAND; GALACTOSYLCERAMIDE; GRANZYME B; MONOCLONAL ANTIBODY; PERFORIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BLAST CELL; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL DIFFERENTIATION; CELL KILLING; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LEUKEMIA CELL; MONOCYTE; MYELOMONOCYTIC LEUKEMIA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFICATION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 0038040624     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402943     Document Type: Article

References (36)

1. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995; 268: 863-865.
2. Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J Exp Med 1997; 186: 109-120.
3. Elewaut D, Kronenberg M. Molecular biology of NK T cell specificity and development. Semin Immunol 2000; 12: 561-568.
4. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21: 573-583.
5. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626-1629.
6. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 1998; 188: 1529-1534.
7. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998; 188: 1521-1528.
8. Sidobre S, Naidenko OV, Sim BC, Gascoigne NR, Garcia KC, Kronenberg M. The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex. J Immunol 2002; 169: 1340-1348.
9. Brutkiewicz RR, Sriram V. Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol 2002; 41: 287-298.
10. Crul M, Mathot RA, Giaccone G, Punt CA, Rosing H, Hillebrand MX et al. Population pharmacokinetics of the novel anticancer agent KRN7000. Cancer Chemother Pharmacol 2002; 49: 287-293.
11. Canchis PW, Bhan AK, Landau SB, Yang L, Balk SP, Blumberg RS. Tissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d. Immunology 1993; 80: 561-565.
12. Exley M, Garcia J, Wilson SB, Spada F, Gerdes D, Tahir SM et al. CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology 2000; 100: 37-47.
13. Spada FM, Bordello F, Sugita M, Watts GF, Koezuka Y, Porcelli SA. Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells. Eur J Immunol 2000; 30: 3468-3477.
14. Racke FK, Clare-Salzer M, Wilson SB. Control of myeloid dendritic cell differentiation and function by CD1d-restricted (NK) T cells. Front Biosci 2002; 7: d978-d985.
15. Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 2001; 167: 3114-3122.
16. Hagihara M, Gansuvd B, Tsuchiya YUT, Masui A, Inoue KTH, Hotta T. Killing activity of human umbilical cord blood-derived TCRValpha24+ NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells. Cancer Immunol Immunother 2001; 51: 1-8.
17. Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K et al. Human invariant valpha24+ natural killer T cells activated by alpha- galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 2000; 99: 229-234.
18. Takahashi T, Nieda M, Koezuka Y, Nicol A, Porcelli SA, Ishikawa Y et al. Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 2000; 164: 4458-4464.
19. Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y et al. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 2001; 97: 2067-2074.
20. Gansuvd B, Hagihara M, Yu Y, Inoue H, Ueda Y, Tsuchiya T et al. Human umbilical cord blood NK T cells kill tumors by multiple cytotoxic mechanisms. Hum Immunol 2002; 63: 164-175.
21. Chen RL, Reynolds CP, Seeger RC. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Cancer Immunol Immunother 2000; 48: 603-612.
22. Proffitt RT, Tran JV, Reynolds CP. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. Cytometry 1996; 24: 204-213.
23. Kataoka T, Takaku K, Magae J, Shinohara N, Takayama H, Kondo S et al. Acidification is essential for maintaining the structure and function of lytic granules of CTL. Effect of concanamycin A, an inhibitor of vacuolar type H(+)-ATPase, on CTL-mediated cytotoxicity. J Immunol 1994; 153: 3938-3947.
24. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998; 188: 2375-2380.
25. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001; 98: 31-36.
26. Emanuel PD, Shannon KM, Castleberry RP. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Mol Med Today 1996; 2: 468-475.
27. Hess JL, Zutter MM, Castleberry RP, Emanuel PD. Juvenile chronic myelogenous leukemia. Am J Clin Pathol 1996; 105: 238-248.
28. Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000; 192: 741-754.
29. Eberl G, MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 2000; 30: 985-992.
30. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002; 195: 625-636.
31. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 2000; 164: 1148-1152.
32. Wilson SB, Byrne MC. Gene expression in NKT cells: defining a functionally distinct CD1d-restricted T cell subset. Curr Opin Immunol 2001; 13: 555-561.
33. Yang OO, Racke FK, Nguyen PT, Gausling R, Severino ME, Horton HF et al. CD1d on myeloid dendritic cells stimulates cytokine secretion from and cytolytic activity of Valpha24JalphaQ T cells: a feedback mechanism for immune regulation. J Immunol 2000; 165: 3756-3762.
34. van der Vliet HJ, Nishi N, Koezuka Y, von Blomberg BM, van den Eertwegh AJ, Porcelli SA et al. Potent expansion of human natural killer T cells using alpha- galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Methods 2001; 247: 61-72.
35. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Jayaprabhu S et al. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clin Cancer Res 2001; 7(Suppl): 804s-810s.
36. Nishi N, van der VIiet HJ, Koezuka Y, von Blomberg BM, Scheper RJ, Pinedo HM et al. Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human V alpha 24+ V beta 11+ T cells in vitro. Hum Immunol 2000; 61: 357-365.